Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Today's Top SOA Links


OriGene Publishes Landmark Paper on Revolutionary Proteome Platform for Antibody Specificity Test
Key Publication Further Validates OriGene's Unique Approach and Application of Protein Microarray Technology to Analyze Antibody Specificity

ROCKVILLE, Md., Jan. 7, 2013 /PRNewswire/ -- OriGene Technologies, Inc. ("OriGene"), one of the industry leaders in producing genome wide products for research and diagnostic applications, has brought the antibody field one step closer to identifying and developing ultra-specific monoclonal antibodies.  Specificity of antibodies for research or clinical applications is of critical importance and therefore it is a "must" to demonstrate antibody specificity with high confidence.  Leveraging more than ten years of product development expertise, OriGene has generated a breakthrough mammalian-cell expressed antigen chip which contains greater than 50% of the human proteome ("Protein Microarray Technology").  OriGene's Protein Microarray Technology key utility is to verify diagnostic and therapeutic antibody specificity and identify cross-reactivity.  Antibody cross-reactivity is a major cause of concern throughout the industry with the development and commercialization of diagnostic and therapeutic antibodies. 

(Logo: http://photos.prnewswire.com/prnh/20130107/DC38100LOGO)

As published in BMC Biotechnology 2012, 12:88, OriGene's Protein Microarray Technology chip was successfully used to evaluate the specificity of the commonly used anti-ERCC1 antibody called 8F1.  This ERCC1 antibody is being explored as a predictive diagnostic biomarker for cisplatin-based chemotherapy.  OriGene was able to utilize its proprietary technology to determine that the 8F1 antibody cross-reacts with a previously unknown nuclear protein called PCYT1A and thus is not suitable for use in IHC assays for ERCC1 detection. (view Abstract)

"This result is important, as it could explain some of the inconsistencies seen in comparative studies done on the 8F1 antibody. Using antibodies which cross-react with a nuclear protein PCYT1A when testing for ERCC1 may potentially lead to an incorrect IHC test result," says Wei-Wu He, Ph.D., who is CEO of OriGene and one of the co-authors of the scientific study.

OriGene utilized its Protein Microarray Technology to screen 18 monoclonal antibodies to identify two unique UltraMAB™ antibody clones, 4F9 and 2E12, and confirmed that these are truly "mono-specific." Every UltraMAB™ antibody is validated for IHC and for immunoassay analysis, and verified to have non-specific cross-reactivity by utilizing OriGene's Protein Microarray Technology. Consequently, each UltraMAB™ is specificity verified to an unprecedented level, ensuring superior performance for IHC applications.  In 2012, OriGene generated over 20 UltraMAB™ antibodies and its future plans are to launch new UltraMAB™ antibodies on a regular basis. 

Detailed information about the Protein Microarray Technology and a complete listing of the UltraMAB™ antibody product line is available at www.origene.com/UltraMAB, where customers can learn more about OriGene's unique approach to ultra-specific monoclonal antibody development.  

About OriGene
OriGene Technologies, Inc. develops, manufactures, and sells genome wide research and diagnostic products worldwide.  OriGene's research business offers one of the world's largest collections of cDNA clones, human proteins, antibodies and assays for use to study gene functions.  Leveraging the recent advances in the human genome, OriGene utilizes its innovative R&D in the U.S. and large scale capacity in China to produce an extensive array of ultra-specific monoclonal antibodies called UltraMAB™ which offers significantly value added diagnostic benefits for disease screening and personalized medicine treatment. OriGene's Protein Microarray Technology is used for QC diagnostic and therapeutic specificity and other protein-protein interactions.   For more information, visit www.OriGene.com.

SOURCE OriGene Technologies, Inc.

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Web 2.0 Latest News
Cryptocurrencies have gained traction in the past half-decade for a variety of reasons. Bitcoin has become the most popular cryptocurrency in the world due to its sudden rise in value and acceptance within the international marketplace. You might be wondering: What does cloud computing...
HP charts a better path to simplified, just-in-time, and pan-IT support improvements -- despite dynamic and complex IT environments. Much of the attention to coping with mega IT challenges such as cloud, bring your own device (BYOD), mobile applications, and big data focuses on adopti...
The IT infrastructure of modern businesses require a number of seemingly never-ending cycles to track assets. As these assets go through different stages of usefulness or functionality, IT teams must constantly manage the process, which takes them away from other more important tasks a...
Moscow-based OpenBank, one of the largest private financial services groups in Russia, has built out a business intelligence capability for wholly new business activity monitoring benefits. The next BriefingsDirect deep-dive big data benefits case study interview explores how Moscow-b...
Don’t emphasize network security at the cost of endpoint security; the two can be integrated and work hand in hand. The result is a safer, more secure business ready for the challenges of the future.
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE